$LIFE

A 4:30 p.m. ET call will follow Ethos' Nov. 2 third-quarter results release.

Ethos Technologies Inc. (NASDAQ: LIFE) will release its Q3 2026 financial results on Nov. 2, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET the same day to discuss the results, with a webcast available on the company's Investor Relations website.

Original reporting
Published Oct 12, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LIFE
Neutral
high confidence
Mentioned
$LIFE
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LIFENeutralLow
01

Why it matters

The earnings‑release notice is routine; traders may position ahead of the call but no specific trade signal is provided.

02

Market read

Announcement of the Q3 2026 earnings date; relevant for short‑term traders monitoring upcoming results.

03

What to watch

Potential hidden guidance or product updates disclosed during the call could move the stock.

Relevance 5/10Novelty 4/10Timing: pre‑market on Nov 2, 2026

Background

Ethos Technologies is a Nasdaq‑listed life‑insurance technology provider that regularly reports quarterly results.

Company-level read

Ticker impact

$LIFENeutralHigh confidence
Context

Ethos Technologies announced it will release its Q3 2026 earnings on Nov. 2, 2026 and host a conference call at 4:30 p.m. ET.

Expected impact

no immediate impact; potential volatility around the Nov 2 earnings release

Evidence & confidence

The news is a standard earnings‑release notice without new guidance or material events.

Market effects

Sets a timeline for life‑insurance‑tech sector earnings updates.

Limited to U.S. investors tracking fintech earnings.

Minimal; primarily relevant to investors in Ethos and comparable insurtech stocks.

Counterpoint

If the market expects weak guidance, the announcement could be a catalyst for a short‑cover rally.

Key entities

  • Ethos Technologies Inc.

    Life‑insurance technology firm (NASDAQ:LIFE).

Related articles

$LIFEMed

JPMorgan downgrades Ethos Technologies stock rating to neutral

JPMorgan downgraded Ethos Technologies (LIFE) to Neutral from Overweight, setting a $37 price target. The stock has surged 99% year-to-date. JPMorgan notes growth potential but cites balanced risk-reward and relative valuation concerns. Ethos reported Q2 2026 revenue of $189.6M, up 113% YoY, and raised full-year guidance to $727M-$731M. Other firms adjusted targets post-results.

$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.